Endothelin B receptor Inhibitors
1 drugsAbout Endothelin B receptor
The Endothelin B receptor (ET<sub>B</sub> receptor) is a G protein-coupled receptor that binds endothelin peptides and participates in physiological processes. Its functions include vasodilation, cell proliferation, and inflammation.
Currently, there is no genetic evidence directly linking the ET<sub>B</sub> receptor to specific diseases. However, its known functions suggest potential therapeutic applications, particularly in the cardiovascular space.
One FDA-approved drug, macitentan, targets the endothelin pathway, demonstrating clinical relevance. Macitentan, a small molecule, was first approved in 2021 and is marketed by Alembic.
Top Endothelin B receptor Drugs
Alembic is the only company with an approved drug targeting the Endothelin B receptor.
Low competition suggests high entry barriers or limited perceived market opportunity.
Endothelin B receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Endothelin B receptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches.
Endothelin B receptor Clinical Trials 55 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Endothelin B receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 14 | 2 | 0 | 88% |
| Phase 2 | 11 | 8 | 3 | 0 | 73% |
| Phase 3 | 23 | 12 | 9 | 2 | 57% |
| Phase 4 | 5 | 3 | 2 | 0 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Endothelin B receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Endothelin B receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Endothelin B receptor Drug Approval Timeline (2021 - 2021)
The first and only drug, macitentan, was approved in 2021.
Recent approval suggests renewed interest, but market saturation may occur quickly.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 10 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Endothelin B receptor. A trial counts if an approved drug acting on Endothelin B receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.